MSD Korea threw a game-changer for the reimbursement expansion of the immunotherapy drug ‘Keytruda.’

According to industry sources, the company has once again submitted a revised cost-sharing proposal to the Health Insurance Review & Assessment Service (HIRA) to expand the reimbursement of ‘Keytruda (pembrolizumab)’ to cover first-line treatment of non-small cell lung cancer (NSCLC). With the submission, the industry’s eyes are on whether the issue will put on the agenda for deliberation by the Cancer Drug Review Committee in May.

If selected, this will be the 8th discussion held by the Committee for Keytruda. The decision for the drug was put on hold at the committee meeting in August